Swiss National Bank Portfolio holdings
The Swiss National Bank (SNB), founded in 1907 and headquartered in Zurich with an office in Bern, is Switzerland’s central bank, responsible for conducting monetary policy, issuing the Swiss franc, and ensuring price stability, while uniquely managing a massive investment portfolio. Unlike most central banks, the SNB is a joint-stock company with shares traded on the SIX Swiss Exchange, owned roughly 55% by public entities like cantons and 45% by private investors, yet it operates independently under federal oversight. It holds over $800 billion in foreign currency reserves as of late 2024—invested in global equities, bonds, and gold—to manage the franc’s value, famously intervening in markets to prevent excessive appreciation, as seen with the 2015 abandonment of the euro peg. Led by Chairman Thomas Jordan until his planned exit in September 2024, the SNB balances its dual role as a monetary authority and a significant global investor, influencing both Swiss and international financial stability.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Teva Pharmaceuticals
TEVA
|
+$145M |
| 2 |
Fortis
FTS
|
+$68.9M |
| 3 |
Intuitive Surgical
ISRG
|
+$47.9M |
| 4 |
Keurig Dr Pepper
KDP
|
+$39.6M |
| 5 |
Medtronic
MDT
|
+$34.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
LNKD
LinkedIn Corporation
LNKD
|
+$63.4M |
| 2 |
Hershey
HSY
|
+$51.3M |
| 3 |
American Tower
AMT
|
+$50.3M |
| 4 |
Alcoa
AA
|
+$34.6M |
| 5 |
LLL
L3 Technologies, Inc.
LLL
|
+$32.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 15.54% |
| 2 | Healthcare | 14.34% |
| 3 | Industrials | 10.58% |
| 4 | Consumer Discretionary | 10.4% |
| 5 | Communication Services | 10.05% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
HSNI
1601
DELISTED
HSN, Inc.
HSNI
| $1.86M | ﹤0.01% |
54,300
| – | – |
|
1602
ICICI Bank
IBN
$107B
| $1.86M | ﹤0.01% |
272,576
| – | – |
|
|
AMED
1603
DELISTED
Amedisys
AMED
| $1.85M | ﹤0.01% |
43,500
| – | – |
|
|
RDUS
1604
DELISTED
Radius Health, Inc.
RDUS
| $1.85M | ﹤0.01% |
48,700
| – | – |
|
|
IMPV
1605
DELISTED
Imperva, Inc.
IMPV
| $1.85M | ﹤0.01% |
48,239
+2,200
| +5% | +$89.3K |
|
1606
AAR Corp
AIR
$5.86B
| $1.84M | ﹤0.01% |
55,800
| – | – |
|
1607
Fossil Group
FOSL
$310M
| $1.84M | ﹤0.01% |
71,141
+2,800
| +4% | +$84.2K |
|
|
SYKE
1608
DELISTED
SYKES Enterprises Inc
SYKE
| $1.84M | ﹤0.01% |
63,723
+2,600
| +4% | +$72.5K |
|
1609
Performance Food Group
PFGC
$17.9B
| $1.84M | ﹤0.01% |
76,500
+20,600
| +37% | +$489K |
|
|
AIRM
1610
DELISTED
Air Methods Corp
AIRM
| $1.83M | ﹤0.01% |
57,600
| – | – |
|
1611
Saia
SAIA
$9.52B
| $1.83M | ﹤0.01% |
41,400
| – | – |
|
1612
Emergent Biosolutions
EBS
$228M
| $1.83M | ﹤0.01% |
55,600
| – | – |
|
|
RRD
1613
DELISTED
RR Donnelley & Sons Co.
RRD
| $1.82M | ﹤0.01% |
+111,745
| New | +$2.01M |
|
|
AMWD
1614
DELISTED
American Woodmark
AMWD
| $1.82M | ﹤0.01% |
24,200
| – | – |
|
1615
NovaGold Resources
NG
$3.37B
| $1.81M | ﹤0.01% |
397,200
+9,300
| +2% | +$42K |
|
1616
Piper Sandler
PIPR
$5.35B
| $1.81M | ﹤0.01% |
100,000
-10,000
| -9% | -$158K |
|
|
GTLS
1617
DELISTED
Chart Industries
GTLS
| $1.81M | ﹤0.01% |
50,300
+2,000
| +4% | +$68.2K |
|
|
BMCH
1618
DELISTED
BMC Stock Holdings, Inc
BMCH
| $1.81M | ﹤0.01% |
92,819
+5,100
| +6% | +$92.5K |
|
1619
Kulicke & Soffa
KLIC
$4.76B
| $1.81M | ﹤0.01% |
113,400
| – | – |
|
1620
Amkor Technology
AMKR
$13.5B
| $1.8M | ﹤0.01% |
171,000
| – | – |
|
1621
Evertec
EVTC
$1.76B
| $1.8M | ﹤0.01% |
101,574
| – | – |
|
|
WSTC
1622
DELISTED
West Corporation
WSTC
| $1.8M | ﹤0.01% |
72,830
| – | – |
|
1623
Adtran
ADTN
$632M
| $1.8M | ﹤0.01% |
80,600
| – | – |
|
|
ASRT
1624
DELISTED
Assertio
ASRT
| $1.8M | ﹤0.01% |
1,662
| – | – |
|
1625
RH
RH
$3.46B
| $1.79M | ﹤0.01% |
58,430
| – | – |
|
Similar funds
Swiss National Bank's Q4 2016 Portfolio in Review
As of Q4 2016, Swiss National Bank held 2,615 positions worth $63.4B, up 1.6% from $62.4B the previous quarter. Its ten largest holdings account for 15% of the portfolio.
Trading was light in Q4 2016: portfolio turnover was 5%. Swiss National Bank opened 79 new positions and exited 51, leaving the 2,615-position portfolio largely intact.
By sector, the portfolio is most concentrated in Technology at 16% of assets, up from 16% a quarter earlier, followed by Healthcare and Industrials.
- Swiss National Bank's largest Q4 2016 buy was Teva Pharmaceuticals: 3,630,251 shares worth $132M.
- Swiss National Bank added most to Intuitive Surgical in Q4 2016, an estimated $47.9M increase.
- Swiss National Bank's biggest Q4 2016 reduction was Hershey, cutting an estimated $51.3M.
- Swiss National Bank fully exited LinkedIn Corporation in Q4 2016, selling an estimated $63.4M.
- Swiss National Bank's ten largest holdings make up 15% of its $63.4B portfolio in Q4 2016.
- Swiss National Bank opened 79 new positions and closed 51 in Q4 2016.
- Swiss National Bank's portfolio value rose 1.6% quarter-over-quarter to $63.4B.
Based on Swiss National Bank's 13F filing for Q4 2016, filed 8 Feb 2017.